May 17, 2017 / 11:41 AM / 4 months ago

BRIEF-FDA puts clinical hold on Concert Pharma's hair loss drug

May 17 (Reuters) - Concert Pharmaceuticals Inc:

* Concert Pharmaceuticals announces clinical hold on ctp-543 phase 2A trial

* Concert Pharmaceuticals says FDA requested review of recently completed non-clinical studies

* Concert Pharmaceuticals - FDA requested review of recently completed non-clinical studies

* Concert Pharmaceuticals - FDA did not cite a safety concern

* Concert Pharmaceuticals - at request of FDA, company intends to submit requested non-clinical study reports promptly

* Concert Pharmaceuticals - FDA intend to review additional non-clinical data as support for one-year dosing duration as planned in phase 2a trial

* Concert Pharmaceuticals - received notice from U.S. FDA that its ctp-543 phase 2a clinical trial for alopecia areata has been placed on clinical hold Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below